glp-1 receptor agonist news How long should you take drugs? Study links longer use to lower heart risk GLP-1 receptor agonists are increasingly

Description

Psychiatry 32 , 117127 (2024)

Canada Europe Germany UK France Spain Italy Switzerland Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa South Africa Saudi Arabia Rest of Middle East & Africa Table of Contents Chapter 1 Methodology & Scope Chapter 2 Executive Summary Chapter 3 Industry Insights Chapter 4 Competitive Landscape, 2022 Chapter 5 Market Estimates and Forecast, By Drug Class (USD Million) Chapter 6 Market Estimates and Forecast, By Route of Administration (USD Million) Chapter 7 Market Estimates and Forecast, By Application (USD Million) Chapter 8 Market Estimates and Forecast, By Distribution Channel (USD Million) Chapter 9 Market Estimates and Forecast, By Region (USD Million) Chapter 10 Company Profiles Don't see your key competitors

The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and glucose-dependent Insulinotropic Polypeptide Dual Agonist

In addition, the increased CSFserum leptin ratios in patients with IIH compared with controls suggest that transfer of leptin over the bloodbrain barrier is not impaired in IIH, in contrast to obesity